UPDATE 1-Forest Labs FY Q2 profit falls short of estimates
* Company leaves full year guidance at $3.60-$3.70/shrOct 18 (Reuters) - Forest Laboratories Inc said on
Tuesday its fiscal second-quarter earnings fell, though new
product sales helped drive a 9 percent increase in sales.The company’s net profit fell to $249.8 million, or 91
cents a share in the second quarter ended Sept. 30, from $286.1
million, or $1 a share, a year ago. Revenue rose to $1.17
billion from $1.04 billion a year ago.Sales rose 9 percent to $1.13 billion, from $1.037 billion
a year ago.Analysts were on average expecting earnings excluding
one-time items of 99 cents a share, according to Thomson
Reuters I/B/E/S. They were expecting revenue of $1.16 billion.Forest stands to lose roughly a quarter of its revenue
after its antidepressant Lexapro loses patent protection early
next year. The company’s Alzheimer’s disease drug, Namenda,
loses patent protection in 2015.Lexapro sales were $596.1 million in the latest quarter
compared with $569.3 million a year ago. Sales of Namenda rose
8.6 percent to $336.8 million.The company said it still expects earnings per share for
the fiscal year ending March 31, 2012 will be in the range of
$3.60-$3.70 a share.Analysts are expecting full-year earnings of $3.76 a share
excluding items, and full-year revenue of $4.49 billion.